Classification of Culturable Bifidobacterial Population from Colonic Samples of Wild Pigs (Sus scrofa) Based on Three Molecular Genetic Methods

2017 ◽  
Vol 74 (11) ◽  
pp. 1324-1331 ◽  
Author(s):  
Radko Pechar ◽  
Jiří Killer ◽  
Chahrazed Mekadim ◽  
Martina Geigerová ◽  
Vojtěch Rada
2017 ◽  
Vol 33 (2) ◽  
pp. 137-140 ◽  
Author(s):  
Antonino Carbone ◽  
Annunziata Gloghini

“Ne è passata di acqua sotto i ponti.” It has been a long time since the diagnosis of Hodgkin lymphoma (HL) was exclusively based on the detection of typical Reed-Sternberg cells and the recognition of the characteristic morpho-histological background, as well as on the pathologist’s skill. The discovery of immunologic, molecular genetic and virologic biomarkers has provided an objective contribution to the diagnosis and a scientific basis for a modern classification of HL. Recent updates have clarified the nature of the so-called nodular lymphocyte predominant HL and its link to the T-cell/histiocyte-rich large B-cell lymphomas as well as its relationship with the lymphocyte-rich subset of classical HL (CHL). Molecular virology studies assessed a role for the Epstein-Barr virus in the pathogenesis of a fraction of CHL of the general population, and virtually in all cases of CHL occurring in people infected by HIV. Finally, immunologic and genetic findings corroborated the existence of grey zone lymphomas at the edges of CHL. Overall, these advances provided additional and useful information to address the treatment of patients affected by HL.


PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0206070 ◽  
Author(s):  
Richard M. Poché ◽  
David Poché ◽  
Greg Franckowiak ◽  
Daniel J. Somers ◽  
Lindsay N. Briley ◽  
...  

2021 ◽  
Author(s):  
Christopher J. O’Bryan ◽  
Nicholas R. Patton ◽  
Jim Hone ◽  
Jesse S. Lewis ◽  
Violeta Berdejo‐Espinola ◽  
...  

2021 ◽  
Vol 6 ◽  
pp. 30-46
Author(s):  
Juhi Singh ◽  
Puneet Kumar ◽  
Khushi Verma ◽  
Satyender Kumar Tiwary ◽  
Gopeshwar Narayan ◽  
...  

Gastric cancer remains highly prevalent and accounts for a notable proportion of global cancer mortality and this is associated with poor survival rates. Understanding the molecular genetic changes of gastric carcinoma may offer an insight into its pathogenesis helps in identifying new biomarkers, aid prognostication, and novel treatment targets. Over a past few decades, advances in technology and high throughput analysis have improved understanding of the molecular genetic aspects of gastric cancer. In this article, hierarchy of the changes at genetic and molecular level including several aspects which are heterogenous and represents a wide spectrum such as tumor suppressor genes, oncogenes, cellcycle regulators, apoptosis, cell-adhesion molecules, loss of heterozygosity, microsatellite instability, and epigenetic changes. The classification of gastric carcinoma at molecular and genetic level as well as hereditary gastric carcinoma is elaborated. The molecular genetic aspects regarding pathogenesis, changes and aberrations of all genes and pathways which are involved in gastric cancer are addressed in this review.


2000 ◽  
Vol 31 (5) ◽  
pp. 532-538 ◽  
Author(s):  
Marc Ladanyi ◽  
Julia A. Bridge

2019 ◽  
Vol 166 ◽  
pp. 105020 ◽  
Author(s):  
Jonas Pereira da Silva ◽  
Irenilza de Alencar Nääs ◽  
Jair Minoro Abe ◽  
Alexandra Ferreira da Silva Cordeiro

2019 ◽  
Vol 19 (5) ◽  
pp. 412-416 ◽  
Author(s):  
Emanuela Molinari ◽  
Olimpia E Curran ◽  
Robin Grant

In 2016, the WHO incorporated molecular markers, in addition to histology, into the diagnostic classification of central nervous system (CNS) tumours. This improves diagnostic accuracy and prognostication: oligo-astrocytoma no longer exists as a clinical entity; isocitrate dehydrogenase (IDH) mutant and 1p/19q co-deleted oligodendroglioma is a smaller category with better prognosis; IDH wild-type ‘low-grade’ glioma has a much poorer prognosis; and glioblastoma is divided into IDH mutant (with an better prognosis than pre-2016 glioblastoma) and IDH wild type (with a poorer prognosis). Previous advice based on phenotype alone will change with respect to median survival, best management plan and response to treatment. There are implications for routine neuropathology reporting and future trial design. Cases that are difficult to classify may need more advanced molecular genetic classification through DNA methylation-based classification of CNS tumours (Heidelberg Classifier). We discuss the practical implications.


Sign in / Sign up

Export Citation Format

Share Document